Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Wakamoto: Profits Down due to Poor Stock Management
June 1, 2009
- Champix Cuts Lifetime Medical Spending by ¥30,000
June 1, 2009
- Average Operating Profit Rate Down to 0.38% for Top-Four Wholesalers
June 1, 2009
- Teijin: Pharma & HHC Business Remains Bullish
June 1, 2009
- JSMI Announces Vision for Activation of OTC Drug Industry
June 1, 2009
- Suzuken: Sharp Fall in Profits Despite 3.4% Increase in Sales
June 1, 2009
- Meiji HD: Generics Bolster Pharma Business
June 1, 2009
- Reform of Profit Structure "Task of Pressing Urgency": Mr Kumakura
June 1, 2009
- Kyowa Kirin: Nesp Injection Plastic Syringe
May 25, 2009
- Mediceo Paltac to Invite 1,000 Employees to Early Retirement
May 25, 2009
- IMS Health Revises Its Forecast for Global Drug Sales Downward
May 25, 2009
- Kyowa Kirin Licenses Anti-LIGHT Antibody to sanofi-aventis
May 25, 2009
- JCR (Japan College of Rheumatology) 2009
May 25, 2009
- Shionogi to Acquire Pain-Focused US Company
May 25, 2009
- CS Yakuhin to Acquire Part of OTC Drugs Wholesale Business from Tomita Health Care
May 25, 2009
- Takeda to Acquire IDM Pharma
May 25, 2009
- Eisai: Profits Show Sharp Rebound with 6.5% Increase in Sales
May 25, 2009
- Santen: Overseas Sales Affected by Strong Yen
May 25, 2009
- Korosho to Invite Public Comments on Proposed Transient Measure
May 25, 2009
- Shionogi: Sales Up 6.2%; Crestor Continues to Drive Business
May 25, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…